Moderna's full pipeline may fuel long-term growth.

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

Moderna (MRNA) ended the recent trading session at $49.56, demonstrating a -7.49% change from the preceding day's closing ...

Continue » Moderna's shares could soar as it advances its mRNA platform. Compared to older vaccines, those of the mRNA ...

They aren't just "pandemic stocks." ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

In high-risk melanoma patients who had undergone complete tumor removal, adding Moderna's mRNA-4157 to Keytruda reduced the risk of recurrence or death by 49% versus Keytruda alone. The combination ...

Signed Memorandum of Understanding supports “Plan Mexico,” Mexico’s strategic initiative to build a local mRNA ecosystem and strengthen health security Strategic agreement will enable access to ...